selected publications
-
Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers.
The Journal of clinical endocrinology and metabolism.
2019
Academic Article
GET IT
Times cited: 126 -
Phase II Study of Lenvatinib in Patients With Progressive, Recurrent or Metastatic Adenoid Cystic Carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2019
Academic Article
GET IT
Times cited: 103 -
Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer.
Cancer.
2017
Academic Article
GET IT
Times cited: 47 -
Amidst the excitement: A cautionary tale of immunotherapy, pseudoprogression and head and neck squamous cell carcinoma.
Oral oncology.
2016
Editorial Article
GET IT
Times cited: 24 -
Unmet needs for patients with salivary gland cancer.
Oral oncology.
2016
Editorial Article
GET IT
Times cited: 6 -
Therapy: Lenvatinib and radioiodine-refractory thyroid cancers.
Nature reviews. Endocrinology.
2015
Comment
GET IT
Times cited: 6 -
Reply to B. O'Sullivan et Al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2015
Letter
GET IT
Times cited: 6 -
Evaluating the potential role of PET/CT in the posttreatment surveillance of head and neck cancer.
Journal of the National Comprehensive Cancer Network : JNCCN.
2015
Conference Paper
GET IT
Times cited: 4